Boston Scientific adds $3 billion, $2 billion revolvers and $6 billion term loan
On February 26, 2026, Boston Scientific entered three new credit agreements with Wells Fargo as administrative agent and terminated its 2021 revolving credit agreement. The $6.000 billion term loan may be drawn only to fund the pending acquisition of Penumbra, Inc., under a merger agreement dated January 14, 2026, which means the company will take on substantial new debt if the deal closes.
Key points
- $3.000 billion 2026 Revolving Credit Agreement matures February 26, 2031, with a Maximum Leverage Ratio of 3.75x
- $2.000 billion 364-day revolving credit agreement, with a ticking fee accruing 120 days after its effective date
- $6.000 billion term loan: $1.000 billion Tranche A and $5.000 billion Tranche B, drawable only at the Penumbra acquisition closing
- Prior 2021 revolving credit agreement, as amended through May 10, 2024, was terminated
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.